Patent intelligence · US
US 8962817
Vectors encoding a paralytic peptide
Vectors encoding a paralytic peptide
Patent details — US 8962817
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 24, 2015
- Expiration
- Feb 19, 2035
- Applicant
- Soricimed Biopharma Inc.
- Claims
- 20
- CPC classes
- A61K, A61K38/00, A61K38/1709, A61P
Quick answer
US 8962817 (Vectors encoding a paralytic peptide) is held by Soricimed Biopharma Inc.. Status: granted. Granted Feb 24, 2015. Expires Feb 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Soricimed Biopharma Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K38/00, A61K38/1709, A61P, A61P17/00, A61P21/00
More from Soricimed Biopharma Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 8962817?
US 8962817 (Vectors encoding a paralytic peptide) is held by Soricimed Biopharma Inc.. Status: granted. Granted Feb 24, 2015. Expires Feb 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8962817?
Soricimed Biopharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 8962817 expire?
Our index shows an expiration date of Feb 19, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.